Systemic sclerosis: Autologous HSCT is efficacious, but can we make it safer?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I/II clinical trial conducted in Japan.Arthritis research & therapy · 2019
   Trial
2. Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.Pharmaceutics · 2026
   Review
3. Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study.Clinical rheumatology · 2024
   Article
4. Regulatory B Cells Contribute to the Clinical Response After Bone Marrow-Derived Mesenchymal Stromal Cell Infusion in Patients With Systemic Sclerosis.Stem cells translational medicine · 2023
   Article
5. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics.Journal of clinical medicine · 2022
   Review
6. Case Report: Chemotherapy-Associated Systemic Sclerosis: Is DNA Damage to Blame?Frontiers in medicine · 2022
   Article
7. Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score.Bone marrow transplantation · 2021
   Article
8. Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis.Journal of blood medicine · 2021
   Review
9. Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days.Bone marrow transplantation · 2021
   Article
10. Mesenchymal stem cell as a novel approach to systemic sclerosis; current status and future perspectives.Cell regeneration (London, England) · 2020
    Review
11. Safety and efficacy of HSCT for systemic sclerosis across clinical trials.Nature reviews. Rheumatology · 2020
    Article
12. [Autologous hematopoietic stem cell transplantation for systemic sclerosis : Position statement of the stem cell therapy working party of the German Society of Rheumatology].Zeitschrift fur Rheumatologie · 2020
    Review
13. Mesenchymal stem cells in systemic sclerosis therapy.Reumatologia · 2020
    Review
14. Adipose-Derived Stem Cells from Systemic Sclerosis Patients Maintain Pro-Angiogenic and Antifibrotic Paracrine Effects In Vitro.Journal of clinical medicine · 2019
    Article
15. Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.Frontiers in immunology · 2018
    Review

Corrections and comments

• Commented on by
  Safety and efficacy of HSCT for systemic sclerosis across clinical trials.2020
• Comment on
  Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as